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Background
After surgical correction of Tetralogy of Fallot (TOF),
residual pulmonary regurgitation (PR), right ventricular
(RV) dilatation and RV failure have been associated with
adverse clinical events and are considered criteria for
pulmonary valve replacement. Cardiovascular magnetic
resonance imaging (CMR) is the gold-standard for eva-
luation of these parameters. However it is an expensive
technique which is not readily available in all hospitals
and outpatient clinics. NT-proBNP is a biomarker
which may overcome these CMR limitations and might
be used as a cost-effective biomarker for monitoring
patients with TF.
The aim of this study is to evaluate whether NT-
proBNP plasma levels may help as a biomarker for mon-
itoring ventricular dilatation, pulmonary valve regurgita-
tion and heart failure in patients with repaired TF
Methods
Single-centre observational prospective study including
40 patients (14.3±6.7 years, mean±standard deviation)
with corrected TOF referred to our MRI unit. Data col-
lection included: Clinical Parameters (electrocardiogram,
chest X-ray, NYHA scale, time since last surgery),
Biochemistry (NT-proBNP levels) and CMR (ventricular
volumetry assessment by 2D-SSFP sequence (TR/TE=3.0/
1.5ms, flip angle=60°, resolution 1.7x1.7x8mm, SENSE=2)
and aortic and pulmonary flow assessment by 2D-phase
contrast flow (TR/TE=4.4/2.4ms, flip angle=10°, resolution
1.5x1.5x8mm, averages=2).
Results
Mean time since last surgery was 13.1±6.3 years. Most
patients were asymptomatic (median NYHA scale 1),
with QRS duration of 125±19 ms and a cardiothoracic
ratio of 0.57±0.1. The mean NT-proBNP was 175±109
ug/ml. CMR analysis revealed a dilated indexed RV-end-
diastolic-volume (RV-EDVi) of 125±32 ml/m2 and
RV-end-systolic-volume (RV-ESVi) of 55±19ml/m2, mod-
erate to severe PR-fraction of 36±17% and good biventri-
cular ejection fraction (RV-EF 56±7%, LV-EF 60±7%).
The statistical analysis showed a statistically significant
correlation between the NT-proBNP and RV dilatation
for both the RV-EDVi (Pearson 0.54, p<0.01) and RV-
ESVi (Pearson 0.52, p<0.01) and also with the PR frac-
tion (Pearson 0.26, p<0.01). There was no statistically
significance found between NT-proBNP and RV-EF
(Pearson=0.26), LV-EF (Pearson 0.24) or any clinical
parameters.
The receiver operating curve analysis evidenced that a
NT-proBNP cut-off value above 145 pg/ml predicts the
presence RV-EDVi dilatation over over percentile 95 [1]
(Sensitivity 71%, specificity 100%), RV-ESVi dilatation
over percentile 951 (Sensitivity 88%, Specificity 89%) and
severe PR>40% (Sensitivity 72%, Specificity 73%).
Conclusions
In patients with surgically corrected TOF, NT-proBNP
levels correlate with RV dilatation and the degree of pul-
monary regurgitation. Ambulatory determination of
NT-proBNP might be an easy, readily available and
cost-effective alternative for follow-up evaluation of
these patients and may help decide when to request an
MRI study for follow-up evaluation
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